Bayer Must Study Side Effects of Permanent Birth Control

Updated on
  • Adverse events include pelvic pain and uterus perforation
  • FDA recommends a boxed warning for sterilization devices

Bayer AG must do a study of its permanent birth control device Essure while it’s on the market to help better understand the potential risks to users, the Food and Drug Administration said Monday.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.